StockHealthcare · Medical Devices

$XTNT

Xtant Medical Holdings, Inc.

Price · $XTNTvia TradingView

AI sentiment · 7d0 articles

No enriched coverage for $XTNT in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $XTNT in the last 30 days.

Xtant Medical Holdings’ revenue drops to USD 20.9M in Q1 2026

Xtant Medical Holdings reported a Q1 2026 revenue of $20.9 million, a significant drop from $32.9 million in Q1 2025, primarily due to the sale of assets and non-recurring license revenue. Despite the decline, the company announced strategic moves like strengthening its balance sheet through asset sales, expanding into the hemostatics market, and integrating Dilon’s sales force, leading to an increased full-year 2026 revenue guidance of $101 million to $105 million.

MAR 3·Medical Buyer

Xtant Medical Holdings receives USD 10.7M from Companion Spine

Xtant Medical Holdings received an additional $10.7 million from Companion Spine, finalizing the total aggregate purchase price of $21.4 million for the sale of Coflex® assets and Paradigm OUS businesses. This payment includes $8.2 million for an unsecured promissory note and $2.2 million from working capital and other adjustments. Xtant Medical plans to use these funds to reduce long-term debt and increase cash liquidity, allowing them to focus on their higher-margin biologics business.

via TradingView

News on $XTNT

All news →